Serum stability & Protein corona
Our service helps drug developers advance nanomedicine formulations through clinical phases by assessing bioavailability and enabling early decision making — rather than testing every formulation the hard way.
Most nanomedicines never reach patients. One reason is often overlooked: the moment a particle meets blood, proteins coat it, and that coat helps decide where it goes and whether it survives. Our workflow delivers an interpreted report on stability and protein corona, using a standardized AF4, light scattering and LC-MS/MS method. This gives teams answers on which particles survive serum and have a favorable corona profile before moving to costly animal and clinical studies.
For teams developing nanomedicines: (targeted) lipid nanoparticles (LNP), polymeric particles, proteins, ADCs and ADX therapeutics.
The moment a nanoparticle enters the blood, proteins coat its surface. This protein corona can change how long the particle circulates, where it ends up and how cells respond to it, and so it shapes the particle's pharmacokinetics.
Measuring the corona takes hands-on knowledge of nanoparticle formulation, particle separation and proteomics. We combine that expertise with a specialized workflow, from serum incubation to an interpreted report.
When similar samples were sent to 17 proteomics facilities, only 1.8% of proteins were identified consistently.¹ We run every project through one documented workflow, so your results stay comparable between formulations and over time.
Exposure to full human serum conditions.
Separation techniques separate particles from unbound protein.
Light scattering and gel electrophoresis check size, stability and bound protein.
LC-MS/MS identifies and quantifies the bound proteins. Every project ends with a written, interpreted report.
Tier 1
Tier 2
Pricing on request.
Dr. Sander de Weerd, founder. Nanomedicine scientist (PhD, Nanomedicine and Drug Targeting) with hands-on experience in nanomedicine formulation, characterization and protein corona research. He is building SerumScreen to make serum characterization routine for nanomedicine developers and advance the field from bench to bedside.
Analytical partner
SerumScreen works with specialists in nanomedicine formulation and characterization, and the analytical work is carried out together with a university laboratory.
Program
Part of the PLNT incubation program. PLNT is a life sciences and health incubator at Leiden Bio Science Park.
About PLNTA pilot slot is a bespoke discounted package, built around your particle and the questions you need answered.
Tell us about your particle and what you want to learn. We will get back to you.
Limited pilot slots available.
Not ready for a pilot? Use the same form to ask a question or start a conversation.
